All In Biotech

Drug Trial Radar · NCT05904886

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 687 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

687

Actual

Start

Sep 14, 2023

Primary completion

May 8, 2025

Study completion Sep 1, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
Jun 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic HCC. Per amendment version 5, following a memo issued by the Sponsor, participants receiving treatment in the atezolizumab plus bevacizumab plus tiragolumab arm are recommended to discontinue tiragolumab treatment unless the investigator decides the benefit outweighs the risk. Participants receiving treatment in atezolizumab plus bevacizumab plus placebo arm must discontinue placebo treatment. Participants may continue receiving active treatment(s) per protocol until loss of clinical benefit or unacceptable toxicity, whichever occurs first.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • AtezolizumabDrug

    Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle.

  • BevacizumabDrug

    Bevacizumab will be administered by IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle.

  • TiragolumabDrug

    Tiragolumab will be administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle.

  • PlaceboOther

    Placebo matching tiragolumab will be administered by IV infusion on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator-assessed Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Time frame: From randomization to the first occurrence of disease progression (PD) or death from any cause, whichever occurs first (up to approximately 21 months)
  2. Overall Survival (OS)Time frame: From randomization to death from any cause (up to approximately 36 months)

Locations

171 sites in 27 countries. Site status is shown where the registry gives one.

  • Genesis Cancer Center

    Hot Springs, Arkansas

  • UCSF Fresno at Community Cancer Institute

    Clovis, California

  • City of Hope Cancer Center

    Duarte, California

  • University of California San Diego Moores Cancer Center

    La Jolla, California

  • University of Southern California

    Los Angeles, California

  • Stanford Cancer Center

    Palo Alto, California

  • Va Palo Alto Health Care System

    Palo Alto, California

  • UCLA Cancer Center

    Santa Monica, California

  • Hartford Healthcare Cancer Institute at Hartford Hospital

    Hartford, Connecticut

  • MedStar Washington Hosp Center

    Washington D.C., District of Columbia

  • Florida Cancer Specialists - Fort Myers (Broadway)

    Fort Myers, Florida

  • Miami VA Healthcare System

    Miami, Florida

  • Florida Cancer Specialist, North Region

    St. Petersburg, Florida

  • University of Illinois

    Chicago, Illinois

  • Norton Cancer Institute - Audubon

    Louisville, Kentucky

  • Ochsner Cancer Inst.

    New Orleans, Louisiana

  • Mercy Medical Center

    Baltimore, Maryland

  • Henry Ford Health System

    Detroit, Michigan

  • Cancer & Hematology Centers of Western Michigan

    Grand Rapids, Michigan

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Minnesota Oncology Hematology Woodbury

    Woodbury, Minnesota

  • Washington Uni School of Medicine

    St Louis, Missouri

  • NYU Langone

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Columbia University

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • James J Peters VA Hospital / Mental Illness Research Education and Clinic Center

    The Bronx, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Thomas Jefferson Uni

    Philadelphia, Pennsylvania

  • North Texas VA Medical Center

    Dallas, Texas

  • Kelsey Seybold Clnic

    Houston, Texas

  • Virginia Mason Medical Center

    Seattle, Washington

  • Swedish Cancer Inst.

    Seattle, Washington

  • Univ of Wisconsin-Madison

    Madison, Wisconsin

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • UZ Antwerpen

    Edegem, Belgium

  • AZ Delta (Campus Rumbeke)

    Roeselare, Belgium

  • Clinicas Oncologicas Integradas - COI

    Rio de Janeiro, Brazil

  • CEDOES - Diagnóstico e Pesquisa

    Vitória, Espírito Santo, Brazil

  • Oncoclínicas do Brasil - BELO HORIZONTE

    Belo Horizonte, Minas Gerais, Brazil

Showing 40 of 171 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.